Investor Presentaiton

4 Business Highlights 21 Covering Structural Heart Diseases 3 Registration Application 5 Clinical Trials 日启明医疗® VENUSMEDTECH VenusP-Valve, TriGUARD3, VenusA-Pro Cardiovalve, Liwen RF, Vitae, PowerX, Leaflex Leading the Chinese TAVR Market ✓ Full-year revenue RMB416 million, YOY up 50.6% ✓ 2021 procedure volume grew to 3600 ✓ Covering hospital 360, sales person 220 ✓ Overseas sales revenue RMB10.51 million YOY up 160.5% Continue to Lead the Market 22 Continue R&D and key product trials ➤ 4 Expected to enter into clinical trials: Cardiovalve(China), Liwen RF(Europe), Venus-Neo, RDN 3 Expected to be launched products: VenusP-Valve, TriGUARD3, VenusA-Pro ➤ Maintaining market share 60%~65% ➤ Hospital coverage 400 above ➤ Sales team 300 above

View entire presentation